On March 13, 2025, the U.S. Court of Appeals for the Federal Circuit issued a decision in the case of In Re: Xencor, Inc. In this Appeal from ...

Debiopharm, Oncodesign Services announce license agreement for use of AbYlink technology for pre-clinical services: Martigny, Switzerland Saturday, April 26, 2025, 17:00 Hrs [IST] ...

Debiopharm further describes AbYlink as a one-step method that results in stable conjugation at defined and invariable sites on the Fc domain of an antibody, with no impact on antigen-binding regions, ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Debiopharm Research & Manufacturing S.A. (Debiopharm, a Swiss-based global biopharmaceutical company aiming to cure cancer and ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...

Rhode Island FC will play against the New England Revolution in the U.S. Open Cup on May 7. The match will be held at Centreville Bank Stadium and streamed on Paramount+. This is Rhode Island FC's ...

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO.

Allen Guo, CEO "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain antibody," said Allen Guo, CEO. "This platform ...